Serum Level of Advanced Glycation End-Products (AGEs) is an Independent Determinant of Plasminogen Activator Inhibitor-1 (PAI-1) in Nondiabetic General Population.

Serum Level of Advanced Glycation End-Products (AGEs) is an Independent Determinant of Plasminogen Activator Inhibitor-1 (PAI-1) in Nondiabetic General Population. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Serum Level of Advanced Glycation End-Products (AGEs) is an Independent Determinant of Plasminogen Activator Inhibitor-1 (PAI-1) in Nondiabetic General Population. Abstract Text:

S Yamagishi,H Adachi,M Takeuchi,M Enomoto,K Furuki,T Matsui,K Nakamura,T Imaizumi,S Yamagishi,H Adachi,M Takeuchi,M Enomoto,K Furuki,T Matsui,K Nakamura,T Imaizumi,S Yamagishi,H Adachi,M Takeuchi,M Enomoto,K Furuki,T Matsui,K Nakamura,T Imaizumi,

Glucose can react nonenzymatically with amino groups of proteins to form senescent macroprotein derivatives termed advanced glycation end-products (AGEs). Recently, AGEs have been shown to play an important role in atherosclerosis even in nondiabetic subjects. However, the molecular mechanism underlying this is not fully understood. We have now investigated whether serum AGE level was an independent determinant of plasminogen activator inhibitor-1 (PAI-1), a major physiological inhibitor of fibrinolysis, in nondiabetic general population. One-hundred and eighty-six nondiabetic Japanese subjects underwent a complete history and physical examination, determination of blood chemistries, PAI-1, and AGEs. Uni- and multivariate analyses were applied for the determinants of PAI-1 levels. The average PAI-1 levels were 29.7+/-23.8 ng/ml in males and 21.8+/-17.1 ng/ml in females, respectively. Univariate regression analysis showed that PAI-1 levels were associated with age (inversely, p=0.003), male (p=0.003), body mass index (BMI) (p<0.001), HDL-cholesterol (inversely, p<0.001), triglycerides (p<0.001), fasting plasma glucose (p<0.001), insulin (p<0.001), uric acids (p<0.001), AGEs (p=0.037), and alcohol intake (p<0.001). By the use of multiple regression analyses, BMI (p<0.001), male (p=0.003), fasting plasma glucose (p=0.005), age (inversely, p=0.017), and AGEs (p=0.034) remained significant. The present study is the first demonstration that serum AGE level was one of the independent determinants of PAI-1 in nondiabetic general population. The AGE-associated thrombogenic abnormality may be involved in atherogenesis in nondiabetic subjects.

Serum Level of Advanced Glycation End-Products (AGEs) is an Independent Determinant of Plasminogen Activator Inhibitor-1 (PAI-1) in Nondiabetic General Population. Publishing Authors By Initials

S Yamagishi,H Adachi,M Takeuchi,M Enomoto,K Furuki,T Matsui,K Nakamura,T Imaizumi,S Yamagishi,H Adachi,M Takeuchi,M Enomoto,K Furuki,T Matsui,K Nakamura,T Imaizumi,S Yamagishi,H Adachi,M Takeuchi,M Enomoto,K Furuki,T Matsui,K Nakamura,T Imaizumi,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Serum Level of Advanced Glycation End-Products (AGEs) is an Independent Determinant of Plasminogen Activator Inhibitor-1 (PAI-1) in Nondiabetic General Population. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Hormone and metabolic research. Hormon- und Stoffw

VOLUME: 39

Page Numbers: 845-8

Journal Abbreviation:

ISSN: 0018-5043

DAY: 9

MONTH: Nov

YEAR: 2007

Serum Level of Advanced Glycation End-Products (AGEs) is an Independent Determinant of Plasminogen Activator Inhibitor-1 (PAI-1) in Nondiabetic General Population. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 177722

Serum Level of Advanced Glycation End-Products (AGEs) is an Independent Determinant of Plasminogen Activator Inhibitor-1 (PAI-1) in Nondiabetic General Population. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Serum Level of Advanced Glycation End-Products (AGEs) is an Independent Determinant of Plasminogen Activator Inhibitor-1 (PAI-1) in Nondiabetic General Population. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Serum Level of Advanced Glycation End-Products (AGEs) is an Independent Determinant of Plasminogen Activator Inhibitor-1 (PAI-1) in Nondiabetic General Population.

AFFILIATION: 1Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine, Kurume, Japan.

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Horm Metab Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Serum Level of Advanced Glycation End-Products AGEs is an Independent Determinant of Plasminogen Activator Inhibitor-1 PAI-1 in Nondiabetic General Population Related Publications

• A novel acetyl-CoA carboxylase inhibitor reduces de novo fatty acid synthesis in HepG2 cells and rat primary hepatocytes.
• Administration of pigment epithelium-derived factor (PEDF) inhibits cold injury-induced brain edema in mice.
• Advanced Glycation End Products (AGEs) and Diabetic Vascular Complications.
• Antiatherogenic effect of isoflavones in ovariectomized apolipoprotein e-deficient mice.
• Bilateral pseudocysts of the auricles.
• CORRELATION BETWEEN BRAIN CATECHOLAMINE AND SEDATIVE ACTION OF RESERPINE.
• Chronic cardiac resynchronization therapy reverses cardiac remodelling and improves invasive haemodynamics of patients with severe heart failure on optimal medical treatment.
• Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
• Colorectal polypectomy and risk of colorectal cancer by subsite: the Fukuoka Colorectal Cancer study.
• Detection of coronary artery stenosis after successful percutaneous coronary intervention by dipyridamole stress portable type signal-averaged electrocardiography: a prospective study.
• Effects of milk fermented byLactobacillus gasseri SBT2055 on adipocyte size in rats.
• FKF1 and GIGANTEA complex formation is required for day-length measurement in Arabidopsis.
• Inhibitors of Advanced Glycation End Products (AGEs): Potential Utility for the Treatment of Cardiovascular Disease.
• LXR Agonist Increases the Lymph HDL Transport in Rats by Promoting Reciprocally Intestinal ABCA1 and apo A-I mRNA Levels.
• Lumbosacral subdural hematoma following a ruptured aneurysmal subarachnoid hemorrhage.
• Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice.
• Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.
• Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species.
• Oxidative stress is related to exercise intolerance in patients with heart failure.
• PTHrP-independent hypercalcemia with increased proinflammatory cytokines and bone resorption in two children with CD19-negative precursor B acute lymphoblastic leukemia.
• Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: A possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes.
• Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication.
• Reply to Letter Regarding Article, "Effect of Autologous Bone-marrow Cell Transplantation on Ischemic Ulcer in Patients With Buerger's Disease".
• Serum Level of Advanced Glycation End-Products (AGEs) is an Independent Determinant of Plasminogen Activator Inhibitor-1 (PAI-1) in Nondiabetic General Population.
• Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects.
• The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose-positron emission tomography.
• The properties of ATPase of synaptic vesicle fraction.
• Vitamin C reversed malfunction of peripheral blood-derived mononuclear cells in smokers through antioxidant properties.
• [Internal secretion and hypertension. Catecholamine metabolism and changes in it.]
• [Prognosis and molecular pathogenesis of adult T-cell leukemia/lymphoma]